

## Contents

1. Description
  - 1.1 Background information
  - 1.2 Applications
2. Recommendations for *in vitro* restimulation of antigen-specific T cells with PepTivator® EBV EBNA-1 – premium grade
  - 2.1 Cell preparation
  - 2.2 Reagent requirements
  - 2.3 Recommendations for reconstitution of PepTivator® EBV EBNA-1 – premium grade
  - 2.4 *In vitro* restimulation of antigen-specific T cells
3. References
4. Appendix: Flask and dish sizes for *in vitro* T cell stimulation

## 1. Description

<b>Components</b>	<p>6 nmol/peptide PepTivator® EBV EBNA-1 – premium grade</p> <p>or</p> <p>60 nmol/peptide PepTivator EBV EBNA-1 – premium grade:</p> <p>Pool of lyophilized peptides, consisting mainly of 15-mer sequences with 11 amino acids (aa) overlap, covering the complete sequence (except the GA region) of the Epstein-Barr nuclear antigen 1 (EBNA-1) of Epstein-Barr virus strain B95-8 (Swiss-Prot Acc. no. P03211).</p>
<b>Capacity</b>	<p>6 nmol (approximately 10 µg) per peptide for stimulation of up to 10<sup>8</sup> total cells or 60 nmol (approximately 100 µg) per peptide for stimulation of up to 10<sup>9</sup> total cells.</p>
<b>Product format</b>	Lyophilized peptides containing stabilizer.
<b>Purity</b>	Each peptide >80%, peptides are individually purified by HPLC. Low endotoxin.
<b>Storage</b>	Store lyophilized product at –20 °C. The expiration date is indicated on the vial label.

*This product contains no preservative and is sterile filtered; always handle under aseptic conditions.*

### 1.1 Background information

Epstein-Barr virus (EBV) is a human  $\gamma$ -herpesvirus with B cell growth transforming ability and lymphomagenic potential. More than 90% of human adults are infected with EBV. Once infected, the virus persists for life as a latent infection of B cells. Latent infection by EBV is associated with cancers of epithelial and B cell origin. T cells are essential for the control of the outgrowth of EBV-infected B cells, as increased numbers of EBV-associated malignancies are observed in immunocompromized patients. In solid organ and hematopoietic stem cell transplantation patients with T cell dysfunction are at risk to develop the life-threatening post-transplant lymphoproliferative disease (PTLD).

The Epstein-Barr nuclear antigen 1 (EBNA-1) protein is involved in the replication of viral episomes and therefore crucial for the persistence of the infection. Its expression is maintained in all latency cycles of infection and in all EBV-associated malignancies. EBNA-1-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells have been found in EBV-infected individuals<sup>1-7</sup>.

The PepTivator® EBV EBNA-1 – premium grade is specially developed for efficient *in vitro* stimulation of EBV EBNA-1-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells, as peptides of 15 amino acid length with 11 amino acid overlap represent the optimized solution for stimulating both CD4<sup>+</sup> and CD8<sup>+</sup> T cells in various applications.<sup>4</sup> Stimulation of T cells with PepTivator EBV EBNA-1 – premium grade causes the secretion of effector cytokines and upregulation of activation markers, which then allows the detection or isolation of EBV EBNA-1-specific T cells. Quantitative, phenotypical, or functional analysis of EBV EBNA-1-specific T cell immunity can provide important information on the natural course of immune responses in healthy or immunocompromised individuals.

### 1.2 Applications

- Detection and analysis of EBV EBNA-1-specific CD4<sup>+</sup> and CD8<sup>+</sup> effector/memory T cells, for example, in PBMCs, by MACS® Cytokine Secretion Assays, intracellular cytokine staining, or other technologies.
- Isolation of viable EBV EBNA-1-specific CD4<sup>+</sup> T cells with the CD154 MicroBead Kit.
- Isolation of viable EBV EBNA-1-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells using MACS Cytokine Secretion Assay – Cell Enrichment and Detection Kits or the CD137 MicroBead Kit for *in vitro* generation of T cell lines/clones for research on immunotherapy in EBV infection.
- Generation of EBV EBNA-1-specific CD4<sup>+</sup> and CD8<sup>+</sup> effector/memory T cells from naive T cell populations for research on immunotherapy and vaccination.
- Pulsing of antigen-presenting cells for research on dendritic cell vaccination.

## 2. Recommendations for *in vitro* restimulation of antigen-specific T cells with PepTivator® EBV EBNA-1 – premium grade

### 2.1 Cell preparation

For induction of cytokine secretion by antigen-specific T cells, best results are achieved by stimulation of fresh PBMCs, whole blood, or other leukocyte containing single-cell preparations from tissues or cell lines. Alternatively, frozen cell preparations can be used.

▲ **Note:** Remove platelets after density gradient separation. Resuspend cell pellet, fill tube with buffer, and mix. Centrifuge at 200×g for 10–15 minutes at 20 °C. Carefully remove supernatant.

▲ **Note:** PBMCs may be stored overnight. The cells should be resuspended and incubated in culture medium as described in 2.4, steps 1–3, but without addition of antigen. The antigen is then added to the culture on the next day.

### 2.2 Reagent requirements

- Culture medium, e.g., RPMI 1640 (# 130-091-440) containing 5% human serum, e.g., autologous or AB serum.  
▲ **Note:** Do not use BSA or FCS because of non-specific stimulation.
- (Optional) Cytokine Secretion Assay Kit. For additional reagent and instrument requirements refer to the data sheet of the respective Cytokine Secretion Assay.
- (Optional) Intracellular cytokine staining, e.g., with Anti-IFN-γ-PE (# 130-091-653). For additional reagent requirements refer to the respective data sheet. For more information on other fluorochrome-conjugates see [www.miltenyibiotec.com](http://www.miltenyibiotec.com).
- (Optional) Intracellular cytokine staining of activated CD4<sup>+</sup> T cells by using, for example, the CD154/IFN-γ/CD4 Detection Kit (# 130-092-814).
- (Optional) CD154 MicroBead Kit (# 130-092-658). For details see the CD154 MicroBead Kit data sheet.
- (Optional) CD137 MicroBead Kit (# 130-093-476). For details see the CD137 MicroBead Kit data sheet.
- (Optional) CytoStim for restimulation of human T cells (# 130-092-172, # 130-092-173). For details see the CytoStim data sheet.
- (Optional) PepTivator CEF MHC Class I Plus – premium grade (# 130-098-426) as a peptide-specific positive control.

### 2.3 Recommendations for reconstitution of PepTivator® EBV EBNA-1 – premium grade

1. For reconstitution of the lyophilized peptide pool take the vial from –20 °C and warm-up to room temperature.  
▲ **Note:** Do not open the vial by removing the rubber-stopper.
2. To dissolve the 6 nmol PepTivator® EBV EBNA-1 – premium grade fill a sterile syringe (0.5 mL) with 200 µL of sterile water. To dissolve the 60 nmol PepTivator® EBV EBNA-1 – premium grade fill a sterile syringe (5 mL) with 2 mL of sterile water.
3. Slowly inject the water with a sterile needle through the center of the rubber-stopper into the vial containing the lyophilized peptide pool.

4. Vortex the solution to completely dissolve the lyophilized peptide pool.  
The concentration of the stock solution of PepTivator® EBV EBNA-1 – premium grade is 30 nmol (approximately 50 µg) of each peptide per mL.
5. Remove the rubber-stopper and aspirate the stock solution with a pipette.
6. To avoid repeated freeze-thaw cycles prepare working aliquots from the stock solution.
7. Store the working aliquots at –80 °C.

### 2.4 *In vitro* restimulation of antigen-specific T cells

▲ **Always include a negative control (without antigen) in the experiment. A positive control (e.g. CytoStim) may also be included.**

1. Wash cells by adding medium, centrifuge at 300×g for 10 minutes. Aspirate supernatant.
2. Resuspend cells in culture medium at 10<sup>7</sup> cells/mL. Plate cells in dishes at a density of 5×10<sup>6</sup> cells/cm<sup>2</sup> (see 5. Appendix: Flask and dish sizes for *in vitro* T cell stimulation).
3. Mix the reconstituted PepTivator® Peptide Pool thoroughly. Add 20 µL of peptide pool stock solution per mL cell suspension. Mix carefully and incubate cells at 37 °C; 5% CO<sub>2</sub>. The final concentration of peptide pool in the cell suspension is 0.6 nmol (approximately 1 µg) of each peptide/mL.

**Cytokine Secretion Assay:** Incubate cells for 3–6 hours.

**CD154 MicroBead Kit:** Incubate cells for 4–16 hours.

**CD137 MicroBead Kit:** Incubate cells for 16–24 hours.

**Intracellular cytokine staining antibodies or kits, e.g., CD154/IFN-γ/CD4 Detection Kit:** Incubate cells for 2 hours, then add 1 µg/mL brefeldin A and incubate for further 4 hours.

4. Collect cells carefully by using a cell scraper, or by pipetting up and down when working with smaller volumes. Rinse the dish with cold buffer. Check microscopically for any remaining cells, if necessary, rinse the dish again.

To proceed with the Cytokine Secretion Assay, the CD154 or CD137 MicroBead Kits, or intracellular cytokine staining, please refer to the respective data sheet.

▲ **Note:** When preparing cells for intracellular cytokine staining, fixed cells may be stored at 2–8 °C for up to 1 week.

### 3. References

1. Khanna, R. *et al.* (1995) Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance. *Virology* 214: 633–637.
2. Blake, N. *et al.* (2000) The importance of exogenous antigen in priming the human CD8<sup>+</sup> T cell response: lessons from the EBV nuclear antigen EBNA1. *J. Immunol.* 165: 7078–7087.
3. Leen, A. *et al.* (2001) Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4<sup>+</sup> T-helper 1 responses. *J. Virol.* 75: 8649–8659.
4. Paludan, C. *et al.* (2002) Epstein-Barr nuclear antigen 1-specific CD4<sup>+</sup> Th1 cells kill Burkitt's lymphoma cells. *J. Immunol.* 169: 1593–1603.
5. Voo, K. S. *et al.* (2002) Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4<sup>+</sup> T cells. *Cancer Res.* 62: 7195–7199.
6. Voo, K. S. *et al.* (2004) Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8<sup>+</sup> T lymphocytes. *J. Exp. Med.* 199: 459–470.
7. Long, H. M. *et al.* (2005) CD4<sup>+</sup> T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. *J. Virol.* 79: 4896–4907.
8. Kiecker, F. *et al.* (2004) Analysis of antigen-specific T-cell responses with synthetic peptides — what kind of peptide for which purpose? *Hum. Immunol.* 65: 523–536.

### 4. Appendix: Flask and dish sizes for *in vitro* T cell stimulation

For *in vitro* T cell stimulation (refer to 2.4) the cells should be resuspended in culture medium, containing 5% of human serum, at a dilution of 10<sup>7</sup> cells/mL. The cells should be plated at a density of 5×10<sup>6</sup> cells/cm<sup>2</sup>. Both the dilution and the cell density are important to assure optimum stimulation.

The following table lists culture plate, dish and flask sizes suitable for different cell numbers. It also indicates the appropriate amount of medium to add.

Total cell number	Medium volume to add	Culture plate	Well diameter
0.15×10 <sup>7</sup>	0.15 mL	96 well	0.64 cm
0.50×10 <sup>7</sup>	0.50 mL	48 well	1.13 cm
1.00×10 <sup>7</sup>	1.00 mL	24 well	1.60 cm
2.00×10 <sup>7</sup>	2.00 mL	12 well	2.26 cm
5.00×10 <sup>7</sup>	5.00 mL	6 well	3.50 cm
Total cell number	Medium volume to add	Culture dish	Dish diameter
4.5×10 <sup>7</sup>	4.5 mL	small	3.5 cm
10.0×10 <sup>7</sup>	10.0 mL	medium	6 cm
25.0×10 <sup>7</sup>	25.0 mL	large	10 cm
50.0×10 <sup>7</sup>	50.0 mL	extra large	15 cm
Total cell number	Medium volume to add	Culture flask	Growth area
12×10 <sup>7</sup>	12 mL	50 mL	25 cm <sup>2</sup>
40×10 <sup>7</sup>	40 mL	250 mL	75 cm <sup>2</sup>
80×10 <sup>7</sup>	80 mL	720 mL	162 cm <sup>2</sup>
120×10 <sup>7</sup>	120 mL	900 mL	225 cm <sup>2</sup>

Refer to [www.miltenyibiotec.com](http://www.miltenyibiotec.com) for all data sheets and protocols. Miltenyi Biotec provides technical support worldwide. Visit [www.miltenyibiotec.com/local](http://www.miltenyibiotec.com/local) to find your nearest Miltenyi Biotec contact.

### Legal notices

#### Limited product warranty

Miltenyi Biotec B.V. & Co. KG and/or its affiliate(s) warrant this product to be free from material defects in workmanship and materials and to conform substantially with Miltenyi Biotec's published specifications for the product at the time of order, under normal use and conditions in accordance with its applicable documentation, for a period beginning on the date of delivery of the product by Miltenyi Biotec or its authorized distributor and ending on the expiration date of the product's applicable shelf life stated on the product label, packaging or documentation (as applicable) or, in the absence thereof, ONE (1) YEAR from date of delivery ("Product Warranty"). Miltenyi Biotec's Product Warranty is provided subject to the warranty terms as set forth in Miltenyi Biotec's General Terms and Conditions for the Sale of Products and Services available on Miltenyi Biotec's website at [www.miltenyibiotec.com](http://www.miltenyibiotec.com), as in effect at the time of order ("Product Warranty"). Additional terms may apply. BY USE OF THIS PRODUCT, THE CUSTOMER AGREES TO BE BOUND BY THESE TERMS. THE CUSTOMER IS SOLELY RESPONSIBLE FOR DETERMINING IF A PRODUCT IS SUITABLE FOR CUSTOMER'S PARTICULAR PURPOSE AND APPLICATION METHODS.

#### Technical information

The technical information, data, protocols, and other statements provided by Miltenyi Biotec in this document are based on information, tests, or experience which Miltenyi Biotec believes to be reliable, but the accuracy or completeness of such information is not guaranteed. Such technical information and data are intended for persons with knowledge and technical skills sufficient to assess and apply their own informed judgment to the information. Miltenyi Biotec shall not be liable for any technical or editorial errors or omissions contained herein.

All information and specifications are subject to change without prior notice. Please contact Miltenyi Biotec Technical Support or visit [www.miltenyibiotec.com](http://www.miltenyibiotec.com) for the most up-to-date information on Miltenyi Biotec products.

#### Licenses

This product and/or its use may be covered by one or more pending or issued patents and/or may have certain limitations. Certain uses may be excluded by separate terms and conditions. Please contact your local Miltenyi Biotec representative or visit Miltenyi Biotec's website at [www.miltenyibiotec.com](http://www.miltenyibiotec.com) for more information.

The purchase of this product conveys to the customer the non-transferable right to use the purchased amount of the product in research conducted by the customer (whether the customer is an academic or for-profit entity). This product may not be further sold. Additional terms and conditions (including the terms of a Limited Use Label License) may apply.

CUSTOMER'S USE OF THIS PRODUCT MAY REQUIRE ADDITIONAL LICENSES DEPENDING ON THE SPECIFIC APPLICATION. THE CUSTOMER IS SOLELY RESPONSIBLE FOR DETERMINING FOR ITSELF WHETHER IT HAS ALL APPROPRIATE LICENSES IN PLACE. Miltenyi Biotec provides no warranty that customer's use of this product does not and will not infringe intellectual property rights owned by a third party. BY USE OF THIS PRODUCT, THE CUSTOMER AGREES TO BE BOUND BY THESE TERMS.

#### Trademarks

MACS, the Miltenyi Biotec logo, and PepTivator are registered trademarks or trademarks of Miltenyi Biotec and/or its affiliates in various countries worldwide.

Copyright © 2020 Miltenyi Biotec and/or its affiliates. All rights reserved.